Penumbra (PEN) Competitors

$322.48 -0.31 (-0.10%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$322.73 +0.25 (+0.08%)

As of 05/13/2026 05:37 PM Eastern

PEN vs. LNTH, ITGR, GEHC, PHG, and ZBH

Should you buy Penumbra stock or one of its competitors? MarketBeat compares Penumbra with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and Zimmer Biomet (ZBH). These companies are all part of the "medical" sector.

How does Penumbra compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.06	$233.56M	$4.15	23.24
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30

99.1% of Lantheus shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lantheus currently has a consensus target price of $99.71, indicating a potential upside of 3.37%. Penumbra has a consensus target price of $361.33, indicating a potential upside of 12.05%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Lantheus had 15 more articles in the media than Penumbra. MarketBeat recorded 23 mentions for Lantheus and 8 mentions for Penumbra. Lantheus' average media sentiment score of 0.60 beat Penumbra's score of 0.03 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Penumbra's net margin of 11.76%. Lantheus' return on equity of 29.32% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Penumbra	11.76%	10.87%	8.45%

Summary

Lantheus beats Penumbra on 10 of the 16 factors compared between the two stocks.

How does Penumbra compare to Integer?

Integer (NYSE:ITGR) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

99.3% of Integer shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Penumbra has a net margin of 11.76% compared to Integer's net margin of 7.64%. Integer's return on equity of 12.83% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Penumbra	11.76%	10.87%	8.45%

Penumbra has lower revenue, but higher earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.64	$102.81M	$4.01	22.28
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30

Integer has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Integer had 2 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for Integer and 8 mentions for Penumbra. Integer's average media sentiment score of 0.67 beat Penumbra's score of 0.03 indicating that Integer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Integer currently has a consensus target price of $98.29, indicating a potential upside of 10.00%. Penumbra has a consensus target price of $361.33, indicating a potential upside of 12.05%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Summary

Penumbra beats Integer on 9 of the 16 factors compared between the two stocks.

How does Penumbra compare to GE HealthCare Technologies?

Penumbra (NYSE:PEN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, GE HealthCare Technologies had 1 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for GE HealthCare Technologies and 8 mentions for Penumbra. GE HealthCare Technologies' average media sentiment score of 0.91 beat Penumbra's score of 0.03 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra presently has a consensus target price of $361.33, indicating a potential upside of 12.05%. GE HealthCare Technologies has a consensus target price of $80.67, indicating a potential upside of 30.34%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Penumbra has a net margin of 11.76% compared to GE HealthCare Technologies' net margin of 9.10%. GE HealthCare Technologies' return on equity of 20.46% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
GE HealthCare Technologies	9.10%	20.46%	5.73%

Penumbra has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

GE HealthCare Technologies has higher revenue and earnings than Penumbra. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30
GE HealthCare Technologies	$20.63B	1.37	$2.08B	$4.18	14.81

Summary

GE HealthCare Technologies beats Penumbra on 8 of the 15 factors compared between the two stocks.

How does Penumbra compare to Koninklijke Philips?

Penumbra (NYSE:PEN) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Penumbra had 3 more articles in the media than Koninklijke Philips. MarketBeat recorded 8 mentions for Penumbra and 5 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.65 beat Penumbra's score of 0.03 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra presently has a consensus target price of $361.33, indicating a potential upside of 12.05%. Given Penumbra's stronger consensus rating and higher possible upside, equities research analysts clearly believe Penumbra is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Penumbra has a net margin of 11.76% compared to Koninklijke Philips' net margin of 5.49%. Koninklijke Philips' return on equity of 13.51% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Koninklijke Philips	5.49%	13.51%	5.48%

Penumbra has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Koninklijke Philips has higher revenue and earnings than Penumbra. Koninklijke Philips is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30
Koninklijke Philips	$20.17B	1.22	$1.01B	$1.17	21.92

Summary

Penumbra beats Koninklijke Philips on 11 of the 15 factors compared between the two stocks.

How does Penumbra compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Penumbra has a net margin of 11.76% compared to Zimmer Biomet's net margin of 9.05%. Zimmer Biomet's return on equity of 13.24% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Penumbra	11.76%	10.87%	8.45%

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.47
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30

Zimmer Biomet presently has a consensus target price of $102.80, indicating a potential upside of 24.35%. Penumbra has a consensus target price of $361.33, indicating a potential upside of 12.05%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by company insiders. Comparatively, 2.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zimmer Biomet had 2 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for Zimmer Biomet and 8 mentions for Penumbra. Zimmer Biomet's average media sentiment score of 0.85 beat Penumbra's score of 0.03 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Zimmer Biomet beats Penumbra on 10 of the 17 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEN vs. The Competition

Export

Metric	Penumbra	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$12.70B	$6.90B	$6.30B	$22.96B
Dividend Yield	N/A	1.72%	2.79%	4.07%
P/E Ratio	74.30	49.93	20.99	28.29
Price / Sales	9.04	39.66	555.98	24.55
Price / Cash	75.09	24.21	42.94	25.11
Price / Book	8.61	6.49	9.70	4.73
Net Income	$177.69M	$158.34M	$3.55B	$1.07B
7 Day Performance	-0.66%	-1.83%	-0.56%	-1.11%
1 Month Performance	-2.88%	-1.10%	1.17%	1.36%
1 Year Performance	11.38%	-2.35%	41.20%	24.41%

Penumbra Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEN Penumbra	3.3802 of 5 stars	$322.48 -0.1%	$361.33 +12.0%	+9.1%	$12.70B	$1.40B	74.30	4,700
LNTH Lantheus	2.5834 of 5 stars	$87.78 +2.7%	$88.86 +1.2%	+22.2%	$5.57B	$1.54B	26.05	1,193	Earnings Report Analyst Forecast
ITGR Integer	2.3431 of 5 stars	$84.10 +0.1%	$98.29 +16.9%	-26.0%	$2.86B	$1.85B	20.97	11,000	Analyst Downgrade
GEHC GE HealthCare Technologies	4.9477 of 5 stars	$61.00 0.0%	$82.00 +34.4%	-16.2%	$27.76B	$20.63B	14.59	54,000	Insider Trade
PHG Koninklijke Philips	2.6858 of 5 stars	$26.27 +0.4%	N/A	+5.9%	$25.19B	$20.17B	24.78	65,340	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PEN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Penumbra (PEN) Competitors

PEN vs. LNTH, ITGR, GEHC, PHG, and ZBH

How does Penumbra compare to Lantheus?

Summary

How does Penumbra compare to Integer?

Summary

How does Penumbra compare to GE HealthCare Technologies?

Summary

How does Penumbra compare to Koninklijke Philips?

Summary

How does Penumbra compare to Zimmer Biomet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEN vs. The Competition

Penumbra Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Penumbra (PEN) Competitors

PEN vs. LNTH, ITGR, GEHC, PHG, and ZBH

How does Penumbra compare to Lantheus?

Which has higher valuation & earnings, LNTH or PEN?

Do institutionals & insiders believe in LNTH or PEN?

Do analysts recommend LNTH or PEN?

Does the media refer more to LNTH or PEN?

Which has more volatility and risk, LNTH or PEN?

Is LNTH or PEN more profitable?

Summary

How does Penumbra compare to Integer?

Do institutionals & insiders believe in ITGR or PEN?

Is ITGR or PEN more profitable?

Which has higher valuation & earnings, ITGR or PEN?

Which has more volatility and risk, ITGR or PEN?

Does the media refer more to ITGR or PEN?

Do analysts recommend ITGR or PEN?

Summary

How does Penumbra compare to GE HealthCare Technologies?

Do institutionals and insiders have more ownership in PEN or GEHC?

Does the media prefer PEN or GEHC?

Do analysts rate PEN or GEHC?

Is PEN or GEHC more profitable?

Which has more risk and volatility, PEN or GEHC?

Which has preferable earnings & valuation, PEN or GEHC?

Summary

How does Penumbra compare to Koninklijke Philips?

Do institutionals and insiders have more ownership in PEN or PHG?

Does the media prefer PEN or PHG?

Do analysts rate PEN or PHG?

Is PEN or PHG more profitable?

Which has more risk and volatility, PEN or PHG?

Which has preferable earnings & valuation, PEN or PHG?

Summary

How does Penumbra compare to Zimmer Biomet?

Is ZBH or PEN more profitable?

Which has higher earnings and valuation, ZBH or PEN?

Do analysts rate ZBH or PEN?

Do insiders & institutionals have more ownership in ZBH or PEN?

Does the media favor ZBH or PEN?

Which has more volatility & risk, ZBH or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEN vs. The Competition

Penumbra Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools